Covered recipient · General Payments record
DAVID PRESCOTT TIETJEN
Allopathic & Osteopathic Physicians Internal Medicine Nephrology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$538.52
20 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $538.52 | 20 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ardelyx, Inc. | $121.19 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $97.77 | 4 |
| Novartis Pharmaceuticals Corporation | $69.89 | 3 |
| AKEBIA THERAPEUTICS INC | $55.52 | 2 |
| Amgen Inc. | $41.06 | 2 |
| Otsuka America Pharmaceutical, Inc. | $36.48 | 2 |
| AstraZeneca Pharmaceuticals LP | $34.28 | 2 |
| Bayer Healthcare Pharmaceuticals Inc. | $24.35 | 1 |
| CALLIDITAS THERAPEUTICS US INC. | $20.19 | 1 |
| Lilly USA, LLC | $19.97 | 1 |
| GlaxoSmithKline, LLC. | $17.82 | 1 |
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
DAVID PRESCOTT TIETJEN
NPI 1508838384 · CMS profile ID 159288
Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology
HUNTSVILLE, AL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1508838384?year=2024&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508838384?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508838384?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- DAVID PRESCOTT TIETJEN, NPI 1508838384, CMS profile ID 159288, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1508838384?year=2024&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
20 matching records · $538.52 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–20 of 20.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Lilly USA, LLC | $19.97 | 12/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155185737 | CMS |
| Novartis Pharmaceuticals Corporation | $13.66 | 12/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087421082 | CMS |
| Novartis Pharmaceuticals Corporation | $33.96 | 12/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087421080 | CMS |
| AKEBIA THERAPEUTICS INC | $27.00 | 08/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145828544 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.68 | 08/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118038350 | CMS |
| CALLIDITAS THERAPEUTICS US INC. | $20.19 | 07/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141518899 | CMS |
| Otsuka America Pharmaceutical, Inc. | $18.24 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118993924 | CMS |
| Otsuka America Pharmaceutical, Inc. | $18.24 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118993922 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.04 | 06/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118038354 | CMS |
| AKEBIA THERAPEUTICS INC | $28.52 | 05/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145825665 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.86 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105623841 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $24.35 | 05/01/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086124902 | CMS |
| Amgen Inc. | $21.94 | 03/28/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117399004 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.42 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105233904 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.04 | 03/08/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118038352 | CMS |
| Amgen Inc. | $19.12 | 03/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117399002 | CMS |
| Novartis Pharmaceuticals Corporation | $22.27 | 02/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1087421070 | CMS |
| Ardelyx, Inc. | $121.19 | 02/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146711273 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $21.01 | 01/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1118038348 | CMS |
| GlaxoSmithKline, LLC. | $17.82 | 01/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116341130 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $86,493.87 | 37 |
| PY2024 | Principal investigator | $77,411.65 | 31 |
| PY2023 | Principal investigator | $244,765.38 | 77 |
| PY2022 | Principal investigator | $437,199.28 | 132 |
| PY2021 | Principal investigator | $475,627.60 | 160 |
| PY2020 | Principal investigator | $841,410.33 | 80 |
| PY2019 | Principal investigator | $476,990.58 | 451 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
77 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $10,937.73 | 12/31/2023 | Non-covered Recipient Entity APOGEE CLINICAL RESEARCH LLC | Cardiovascular Renal and Metabolism Lokelma Hyperkalemia | No dispute reported | 06/30/2026 | 991124929 |
| Principal investigator 1 | AstraZeneca UK Limited | $8,117.59 | 12/31/2023 | Non-covered Recipient Entity APOGEE CLINICAL RESEARCH LLC | A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 | No dispute reported | 06/30/2026 | 991139669 |
| Principal investigator 1 | CSL Behring | $1,050.00 | 11/10/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973655 |
| Principal investigator 1 | CSL Behring | $189.00 | 11/10/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973679 |
| Principal investigator 1 | CSL Behring | $3,024.00 | 11/03/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972861 |
| Principal investigator 1 | CSL Behring | $2,277.90 | 11/03/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973487 |
| Principal investigator 1 | CSL Behring | $300.00 | 11/03/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973507 |
| Principal investigator 1 | CSL Behring | $756.00 | 11/03/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973534 |
| Principal investigator 1 | CSL Behring | $4.53 | 11/03/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042973553 |
| Principal investigator 1 | CSL Behring | $71.24 | 10/27/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972441 |
| Principal investigator 1 | CSL Behring | $189.00 | 10/27/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972459 |
| Principal investigator 1 | CSL Behring | $500.00 | 10/27/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972482 |
| Principal investigator 1 | CSL Behring | $1,050.00 | 10/27/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972507 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $624.38 | 10/18/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921947 |
| Principal investigator 1 | CSL Behring | $2,524.50 | 10/16/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042972169 |
| Principal investigator 1 | CSL Behring | $6,703.20 | 10/04/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971985 |
| Principal investigator 1 | CSL Behring | $150.00 | 09/29/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971745 |
| Principal investigator 1 | CSL Behring | $174.74 | 09/29/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971765 |
| Principal investigator 1 | CSL Behring | $300.00 | 09/29/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971789 |
| Principal investigator 1 | CSL Behring | $750.00 | 09/29/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971811 |
| Principal investigator 1 | CSL Behring | $150.00 | 09/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971659 |
| Principal investigator 1 | CSL Behring | $450.00 | 09/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971679 |
| Principal investigator 1 | CSL Behring | $1,805.00 | 09/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971701 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $360.00 | 08/17/2023 | Non-covered Recipient Entity NEPHROLOGY CONSULTANTS, LLC | Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 991124541 |
| Principal investigator 1 | CSL Behring | $212.50 | 07/26/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929495 |
| Principal investigator 1 | CSL Behring | $120.00 | 07/26/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929507 |
| Principal investigator 1 | CSL Behring | $48.00 | 07/20/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929463 |
| Principal investigator 1 | CSL Behring | $192.00 | 07/20/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929479 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $135.00 | 07/19/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921815 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $500.00 | 07/19/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921837 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $500.00 | 07/19/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921925 |
| Principal investigator 1 | CSL Behring | $3,150.00 | 07/14/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971245 |
| Principal investigator 1 | CSL Behring | $425.00 | 06/30/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929365 |
| Principal investigator 1 | CSL Behring | $321.98 | 06/23/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971163 |
| Principal investigator 1 | CSL Behring | $900.00 | 06/23/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971183 |
| Principal investigator 1 | CSL Behring | $934.30 | 06/23/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971205 |
| Principal investigator 1 | CSL Behring | $1,805.00 | 06/23/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042971221 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $2,000.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921771 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $1,500.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921795 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $270.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921881 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $135.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921903 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $27.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921969 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $27.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921989 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $27.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922013 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $27.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922037 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $27.00 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922059 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $26.75 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922083 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $26.75 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922109 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $26.75 | 06/20/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999922131 |
| Principal investigator 1 | CSL Behring | $7,513.20 | 06/09/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042970207 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $889.59 | 06/09/2023 | Non-covered Recipient Entity FRESENIUS MANAGEMENT SERVICES | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | No dispute reported | 06/30/2026 | 1006175765 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,499.91 | 06/09/2023 | Non-covered Recipient Entity FRESENIUS MANAGEMENT SERVICES | A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P | No dispute reported | 06/30/2026 | 1006175775 |
| Principal investigator 1 | CSL Behring | $64.00 | 06/07/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929333 |
| Principal investigator 1 | CSL Behring | $85.50 | 06/07/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929349 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $67,333.10 | 05/22/2023 | Non-covered Recipient Entity APOGEE CLINICAL RESEARCH LLC | Cardiovascular Renal and Metabolism Lokelma Hyperkalemia | No dispute reported | 06/30/2026 | 991136777 |
| Principal investigator 1 | CSL Behring | $11,129.40 | 05/05/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042969827 |
| Principal investigator 1 | CSL Behring | $3.40 | 04/27/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929301 |
| Principal investigator 1 | CSL Behring | $96.00 | 04/24/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929201 |
| Principal investigator 1 | CSL Behring | $128.00 | 04/24/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,600.00 | 04/17/2023 | Non-covered Recipient Entity Nephrology Consultants | EMPA KIDNEY | No dispute reported | 06/30/2026 | 1007645907 |
| Principal investigator 1 | AstraZeneca UK Limited | $41,124.55 | 04/10/2023 | Non-covered Recipient Entity NEPHROLOGY CONSULTANTS, LLC | A Phase 2a Randomized Double blind Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease | No dispute reported | 06/30/2026 | 991124447 |
| Principal investigator 1 | CSL Behring | $240.00 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929015 |
| Principal investigator 1 | CSL Behring | $212.50 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929029 |
| Principal investigator 1 | CSL Behring | $120.00 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929045 |
| Principal investigator 1 | CSL Behring | $127.50 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929059 |
| Principal investigator 1 | CSL Behring | $72.00 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929071 |
| Principal investigator 1 | CSL Behring | $85.50 | 03/23/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929085 |
| Principal investigator 1 | CSL Behring | $1,500.00 | 02/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042969337 |
| Principal investigator 1 | CSL Behring | $2,000.00 | 02/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042969355 |
| Principal investigator 1 | CSL Behring | $8,800.00 | 02/06/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042969377 |
| Principal investigator 1 | CSL Behring | $425.00 | 02/02/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042928929 |
| Principal investigator 1 | CSL Behring | $240.00 | 02/02/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042928945 |
| Principal investigator 1 | CSL Behring | $240.00 | 02/02/2023 | Non-covered Recipient Entity Nephrology Consultants, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1042929677 |
| Principal investigator 1 | CSL Behring | $13.30 | 02/02/2023 | Non-covered Recipient Entity Frenova, LLC | A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis | No dispute reported | 06/30/2026 | 1057937179 |
| Principal investigator 1 | AstraZeneca UK Limited | $27,020.09 | 01/25/2023 | Non-covered Recipient Entity APOGEE CLINICAL RESEARCH LLC | A Phase 2b multicentre randomized double-blind placebo-controlled parallel group dose ranging study to assess the efficacy safety and tolerability of zibotentan and dapagliflozin in patients with chronic kidney disease with estimated glomerular filtration rate eGFR between 20 and 60 mL min 1.73 m2 | No dispute reported | 06/30/2026 | 991135083 |
| Principal investigator 1 | AKEBIA THERAPEUTICS INC | $1,200.00 | 01/19/2023 | Non-covered Recipient Entity Apogee Clinical Research, LLC | A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects | No dispute reported | 06/30/2026 | 999921857 |
| Principal investigator 1 | Alexion Pharmaceuticals, Inc. | $1,180.00 | 01/04/2023 | Non-covered Recipient Entity APOGEE CLINICAL RESEARCH LLC | Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | No dispute reported | 06/30/2026 | 991131275 |